Guardant Health, Inc. (GH) is a Healthcare stock trading at $131.80 (as of 2026-06-18), with a market capitalization of $17.20B and a trailing P/E of -38.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Guardant Health provides liquid biopsy-based diagnostic tests and supporting software/data resources for oncology care and research. Its offerings include Guardant360 blood tests and GuardantINFORM, an in-silico platform using clinical-genomic datasets, along with additional test programs and solutions for connecting patient results with relevant clinical trials.